降纤酶治疗心源性脑栓塞

目的　探讨降纤酶治疗心源性脑栓塞病人的疗效和安全性。　方法　 2 6例心源性脑栓塞病人均有心房纤颤病史 ,男 1 0例 ,女 1 6例 ,年龄 4 0～ 78岁 ,平均 ( 5 1 .73± 1 1 .1 9)岁。给予降纤酶 1 0 u,每日 1次静滴 ,7天为 1疗程。用药期间监测血浆纤维蛋白原、血小板计数、出凝血时间及肝肾功能。　结果　降纤酶治疗心源性脑栓塞疗效确切 ,能改善神经功能 ,总有效率为 88.4 6 % ,早期应用效果更好。无任何不良反应。　结论　降纤酶是一种安全、有效的治疗心源性脑栓塞的药物 ,宜早期、足量、长疗程应用。     

蕲蛇酶治疗急性血栓性深部静脉炎110例临床观察

目的 观察蕲蛇酶治疗急性血栓性小腿深部静脉炎的临床疗效。方法 将162例急性血栓性小腿深部静脉炎患者分为治疗组110例,对照组52例 ;治疗组用蕲蛇酶治疗,对照组用丹参粉治疗。治疗前后分别检查血液流变学指标。结果 治疗组总有效率98．2％,对照组总有效率78．8％,两组疗效比较有显著性差异（P＜0．01）。治疗组治疗后纤维蛋白原含量、全血粘度、血浆粘度、红细胞压积、血沉、血小板聚集率与治疗前比较均有下降,差异显著（P＜0．01或P＜0．05）。对照组除血沉外,其余各项血液流变学指标治疗前后无显著性差异（P＞0．05）。结论 蕲蛇酶是溶栓和预防血栓形成的理想药物。     

降纤酶治疗急性缺血性脑血管病的疗效观察

目的 观察应用降纤酶治疗急性缺血性脑血管病的疗效。方法 将急性缺血性服血管病患者105例,随机分为治疗组和对照组。治疗线54例,用降纤酶10u（体重在60kg以下得5u）加生理盐水250ml静脉滴注,每天1次,连用3天,第4天后改为隔日静滴1次,降纤酶总量达到60u;对照组51例,用复方丹参20ml加0．9％生理盐水250ml静脉滴汪,每天1次,连用14天为1个疗程。于治疗后第7天、第14天检测两组治疗前后的神经功能缺损评分和日常生活能力评分,以评价其临床疗效。于治疗后第7天、第14天检测两组治疗前后的神经功能缺损评分和日常生活能力评分,以评价其临床疗效。结果 治疗组的有效率和显效率分别达到87．03％和62．9％,而对照组的有效率和显效率分别为60．78％和37．25％,两组比较有显著性差异（P＜05）。两组治疗后的日常生活能力和神经功能缺损评分均有显著性差异（P＜0．01）,血液流变学指标有明显的改善（P＜0．01）。结论 降纤酶具有降低血浆纤维蛋白原、改善微循环、降低全血粘度等作用,是治疗急性缺血性脑血管病安全、有效的药物。     

降纤酶联合尼莫地平治疗椎基底动脉系TIA30例分析

目的：观察降纤酶联合尼莫地平对椎基底动脉系一过氧缺血（TIA）发作的疗效。方法：将60例椎基底动脉系TIA患者随机分为降纤酶加尼莫地平治疗组和培他啶对照组各30例。结果：治疗组治疗后第1天、第3天终止发控制率分别为60．3％和90％,均显著高于对照组的16．6％和50％（P＜0．01）。治疗组治疗后血液粘度及纤维蛋白原明显降低。结论：降纤酶联合尼莫地平治疗椎基底动脉系TIA有良好的疗效,对预防其进展及脑梗死有明显的作用。     

降纤酶治疗脑梗死的临床观察

目的　观察国产降纤酶治疗脑梗死的临床疗效、毒副作用以及对血浆纤维蛋白原、凝血酶原时间的影响。　方法　对 CT或 MRI确诊的脑梗死病人 33例 ,按随机方法分为治疗组与对照组 ,分别于治疗前后测定神经功能缺损评分、纤维蛋白原、凝血酶原时间及肝、肾功能并进行对比分析。　结果　降纤酶治疗后神经功能缺损明显改善 ( P <0 .0 0 1 )并且治疗后 1天即出现明显效果 ( P <0 .0 0 5 ) ,总有效率明显高于对照组 ( P <0 .0 5 ) ;血浆纤维蛋白原明显下降 ,与对照组相比 P <0 .0 5 ;治疗过程中未见不良反应。　结论　降纤酶治疗脑梗死疗效显著 ,起效快 ,较安全。     

降纤酶治疗高粘血症40例报告

目的：观察降纤酶治疗高粘血症患者的临床疗效。方法用生理盐水２５０ｍｌ加降纤酶５ｕ,体重超过６５ｋｇ和１０ｕ,静脉滴注,每天１次,连用３天,第４天停用,第５天开始隔天静脉滴注降纤酶５ｕ或者１０ｕ,总量６０ｕ。结果降纤酶能明显地降低高粘血症患者的血液粘度、纤维蛋白原、红细胞聚集指数、微循环滞留时间等,同时也能使患者原有临床症状和体征以及微循环得到明显改善,结论降纤酶是治疗高粘血症的有效药物。     

降纤酶与抗栓酶-3号联合应用治疗脑梗死40例疗效观察

降纤酶是国产蛇毒类新型溶栓抗凝药物 ,它是采用高科技分离提纯的单一组份酶制剂 ,能降解血浆纤维蛋白原 (FG) ,减少血小板粘附聚集 ,促进血管内皮细胞释放 t- PA (组织纤溶酶原激活物 ) ,降低 PAL - I (组织纤溶酶原激活物 - l) ,使形成的纤维蛋白很快被清除 ,并能抑制红细胞聚集 ,缩短红细胞通过时间 ,从而起到降低全血粘度 ,改善微循环 ,加速血栓溶解 ,使阻塞的血管再通和防止血管再栓塞的作用。而抗栓酶 - 3号已被广泛应用于临床多年 ,具有抗凝、溶栓、去纤、抗血小板粘附、聚集等作用。我院于 1 998～ 1 999年联合应用降纤酶与抗栓…     

降纤酶治疗急性脑梗死疗效观察

目的　探讨降纤酶治疗急性脑梗死的疗效　方法　采用随机抽样分组方法 ,将 60例病人分为治疗组和对照组 ,治疗组在对照组的治疗基础上 ,加用降纤酶首量 1 0 u加入生理盐水 2 50 ml中静滴 ,以后 5u,隔天 1次 ,共 4次为 1疗程。疗程结束后进行疗效比较　结果　治疗组显效率 90 % ,对照组显效率 4 3.3% ;血浆纤维蛋白原治疗组显著下降 ,对照组无明显变化　结论　降纤酶降低纤维蛋白原显著 ,并具有抗凝、溶栓、降低血液粘滞度的作用 ,治疗急性脑梗死疗效确切 ,无毒副作用     

降纤酶治疗急性脑梗死双盲对照研究

目的 观察降纤酶治疗急性脑梗死的临床疗效。方法 用国产双盲编号的降纤酶静滴治疗发病２４ｈ内的急性脑梗死患者６５例（治疗组３１例、对照组３４例）,并同时于治疗前、后进行神经功能缺损评分及检测血浆纤维蛋白原（ＦＧ）、凝血酶原时间（ＰＴ）、凝血酶原活动度（ＰＡ）。结果 神经功能缺损评分显著进步率,降纤酶治疗组７４．２％,明显优于对照组２９．２％,两组比较有显著性差异（Ｐ〈０．０１）;治疗组ＦＧ降低明显优     

大剂量降纤酶治疗急性脑梗死的临床研究

目的 探讨大剂量降纤酶治疗急性脑梗死的临床疗效及作用机制。方法 将收治的90例发病在72h内的急性脑梗死患者随机分为大剂量降纤酶组（A组）、中等剂量降纤组（B组）、丹参注射液治疗组（C组）,每组各为30例,A组每天给予降纤酶20u加入0.9%氯化钠注射液250ml中静滴1h以上,每天1次,连用3天,总剂量60u;B组每天用降纤酶10u,连用3天,总剂量30u;C组给予丹参注射液20ml加入5％葡萄糖注射液250ml中静滴,每天1次,连用7天。3个组在用药前后以神经功能缺损程度为指标进行评价,并观察治疗前后血液流变学变化。结果 A组总有效率96．7％,显效率90％,优于B组（总有效率80％,显效率63．3％）,明显优于C组（总有效率60％,显效率33．3％）。A组、B组治疗后血纤维蛋白原明显降低,血粘度得到改善,且A组优于B组。结论 大剂量降纤酶治疗急性脑梗死疗效优于中等剂量降纤酶和常规药物。其主要机制是降低血纤维蛋白原,改善血粘度,从而改善了微循环;增强t-PA,溶解血栓。该药安全可靠,未见自发性出血症状和过敏反应,对肝、肾功能、凝血功能无明显影响,随访3个月稳定性好。     

Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis

It has now been over twenty years since a novel herpesviral genome was identified in Kaposi's sarcoma biopsies. Since then, the cumulative research effort by molecular biologists, virologists, clinicians, and epidemiologists alike has led to the extensive characterization of this tumor virus, Kaposi's sarcoma-associated herpesvirus(KSHV; also known as human herpesvirus 8(HHV-8)), and its associated diseases. Here we review the current knowledge of KSHV biology and pathogenesis, with a particular emphasis on new and exciting advances in the field of epigenetics. We also discuss the development and practicality of various cell culture and animal model systems to study KSHV replication and pathogenesis.     

The structure, reproduction and taxonomy of Vidalia and Osmundaria (Rhodophyta, Rhodomelaceae)

Comprises species occurring mostly in subtidal habitats in tropical, subtropical and warm-temperate areas of the world. An analysis of the type species, V. spiralis (Sonder) Lamouroux ex J. Agardh, a species from Australia, establishes basic characters for distinguishing species in the genus. These characters are (1) branching patterns of thalli, (2) flat blades that may be spiralled on their axis, (3) width of the blade, (4) primary or secondary derivation of sterile and fertile branchlets and (5) position of sterile and fertile branchlets on the thalli. Application of the latter two characters provides an important basic method for separation of species into three major groups. Osmundaria , a genus known only in southern Australia, was studied in relation to Vidalia , and its separation from the Vidalia assemblage is not accepted. Species of Vidalia therefore are transferred to the older genus name, Osmundaria. Two new species, Osmundaria papenfussii and Osmundaria oliveae are described from Natal. Confusion in the usage of the epithet, Vidalia fimbriala Brown ex Turner has been clarified, and Vidalia gregaria Falkenberg, described as an epiphyte on Osmundaria pro/ifera Lamouroux, is revealed to be young branches of the host, Osmundaria prolifera.     

New or rare chromosome counts in Artemisia L. (Asteraceae, Anthemideae) and related genera from Kazakhstan

Fifteen chromosome counts of six Artemisia taxa and one species of each of the genera Brachanthemum, Hippolytia, Kaschgaria, Lepidolopsis and Turaniphytum are reported from Kazakhstan. Three of them are new reports, two are not consistent with previous counts and the remainder are confirmations of very scarce (one to four) earlier records. All the populations studied have the same basic chromosome number, x = 9, with ploidy levels ranging from 2x to 6x. Some correlations between ploidy level, morphological characters and distribution are noted.     

肝癌中HBV和HCV基因和抗原的分布及意义

采用原位分子杂交方法检测HCV RNA及HBV X基因;采用免疫组织化学方法研究HCV核心抗原,非结构区C33c抗原及HBxAg在肝细胞肝癌中的定位及分布.结果表明(1)HCV RNA、HBV X基因在肝细胞肝癌组织检出率分别为40%(55/136)和82%(112/136).HCV RNA定位于癌细胞的胞浆内,阳性细胞呈散在、灶状及弥漫分布三种形式;HBV X基因在肝癌细胞中的分布呈胞浆型、核型及核浆型,阳性细胞也呈上述三种分布形式;(2)HCV C33c抗原、核心抗原在肝细胞肝癌中的阳性率为81%(133/164)及86%(141/164).C33c抗原定位于癌细胞及肝细胞的胞浆内;核心抗原既定位于癌细胞核中,又可定位于胞浆中.C33c抗原阳性细胞以灶状分布为主;而核心抗原阳性细     

Selection with two alleles and complete dominance

For a plant selection model with frequency-independent viabilities, fertilities and selfing rates, it is shown that apart from global fixation, for certain parameter combinations a protected polymorphism and facultative fixation (either allele may become fixed according to initial frequencies) may both occur. Facultative fixation requires different selling rates for the dominant and recessive type. Protection of the polymorphism requires resource allocation for male and female function. In this connection the problem of purely genetically caused population extinction is discussed.
For general frequency dependence and regular segregation, the chances for establishment of a completely recessive gene are compared to those of a completely dominant gene. It is proven that the process of establishment of the recessive gene, despite a fitness advantage, may be considerably endangered by drift effects if random mating prevails. The recessive gene may reach the same effectivity in establishment as a dominant gene, only if the recessive homozygote mates exclusively with its own type during the period of establishment.